Venus Remedies establishes pre-clinical proof of concept for DPPC

25 Apr 2012 Evaluate

Venus Remedies has established pre-clinical proof of concept for its Drug-Protein-Polymer-Conjugate (DPPC). DPPC concept is a novel, patent protected technology, which will help in alleviating cancer specific and selective targeting of tumor cells.

The escalating prevalence of cancers of all kinds and the ever rising unmet need in the field of cancer treatment has made Venus to tap a huge market potential in the first year of the DPPC’s launch itself. This technology would bring revolution to the existing target anti-cancer therapies. The company is all geared up to commercially launch this novel triple conjugate therapy hopefully by next 2-3 years.

The company is also contributing successfully in the oncology segment across the globe through its wide array of key products, which includes Docetaxel, Paclitaxel, Gemcitabine, Oxaliplatin, Irinotecan and Topotecan. The company is also focusing on the anti-infective segment which is posing a threat to the mankind worldwide. Venus Medicine Research Centre (VMRC) is putting great efforts to come out with revolutionary drugs to eradicate these deadly infections.

Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×